$SION News

Citizens Reiterates Market Outperform on Sionna Therapeutics, Maintains $63 Price Target

Stifel Maintains Buy on Sionna Therapeutics, Raises Price Target to $55

BTIG Reiterates Buy on Sionna Therapeutics, Maintains $58 Price Target

Sionna Therapeutics Q1 EPS $(0.60) Misses $(0.51) Estimate

Wedbush Initiates Coverage On Sionna Therapeutics with Outperform Rating, Announces Price Target of $53

Jones Trading Maintains Buy on Sionna Therapeutics, Raises Price Target to $63

BTIG Reiterates Buy on Sionna Therapeutics, Maintains $58 Price Target

Sionna Therapeutics Completes Enrollment In PreciSION CF Phase 2a Proof-Of-Concept Trial

Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $50

BTIG Reiterates Buy on Sionna Therapeutics, Maintains $58 Price Target

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Sionna Therapeutics Q4 EPS $(0.46) Beats $(0.55) Estimate

Sionna Therapeutics Q4 EPS $(0.46) Beats $(0.55) Estimate

Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum

Citizens Initiates Coverage On Sionna Therapeutics with Market Outperform Rating, Announces Price Target of $63

Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit

Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Sionna Therapeutics, Inc. (SION) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript